Amgen Inc. AMGN announced that an appeals court ruled in its favor, upholding the validity of two patents on its blockbuster rheumatoid arthritis drug Enbrel against Novartis’ NVS generic arm, Sandoz.Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen, generating sales of $1.15 billion in the first quarter of 2020.